House Rx Raises $55M to Expand Specialty Pharmacy Model

House Rx, a company focused on making specialty medications more accessible and affordable for patients, has raised $55 million in Series B equity and debt to expand its in-clinic specialty pharmacy model.

The San Francisco-based startup notes that regulators and states are actively challenging the pharmacy benefit manager-owned, closed network specialty pharmacy model. 

House Rx says it offers an alternative vision – a nationwide network of locally owned, brick-and-mortar specialty dispensaries embedded in specialty clinics. The company says this model puts patients and providers at the center and delivers superior quality outcomes. 

By partnering with specialty clinics to integrate pharmacy services directly into care delivery, House Rx says it enables providers to offer high-touch, local alternatives to centralized pharmacy fulfillment models. The company adds that this approach improves coordination between providers and pharmacists, reduces administrative complexity, and delivers better outcomes for patients dealing with complex conditions.

To date, House Rx has partnered with more than 1,000 providers at 80 clinic sites nationwide, helping them stand up and operate in-house pharmacies. House Rx processes approximately $1.5 billion in specialty scripts per year, with that volume expected to increase to $3 billion by the end of 2026.

"There's finally momentum behind creating a specialty pharmacy system that makes it easier for patients to seamlessly and more affordably access the medications they desperately need," said Ogi Kavazovic, CEO and founder of House Rx, in a statement. "We're seeing interest from stakeholders across the healthcare system — healthcare providers, manufacturers, payers, investors, and certainly employees who all recognize the opportunity to finally challenge the status quo in specialty pharmacy. We all want to do better by patients and help bring down the overwhelming expense to our healthcare system. With the support of this funding, we're ready to scale operations to meet the exploding demand.”

In April, House Rx announced its"Smart PA" AI feature, making prior authorizations in pharmacy 80% automated. The company is now investing in several more AI capabilities that will come natively as part of its pharmacy management system.

The financing was led by New Enterprise Associates (NEA) and Town Hall Ventures and included participation from LRVHealth, First Round Capital, Bessemer Venture Partners, and Silicon Valley Bank. This new investment brings the company's total capital raised to date to $100 million.